Mapping the emergence of clusters of biotech firms specializing in drug discovery in Denmark and Sweden from 1997 to 2004 we find that Denmark faster and to a higher extent concentrated activities in the mid-sized categories of firms and also earlier and more steeply increased key outputs such...